Edmonton protocol
From Wikipedia, the free encyclopedia
The Edmonton Protocol is a method of implantation of pancreatic islets for the treatment of type 1 diabetes mellitus, specifically "brittle" type 1 diabetics prone to hypoglycemic unawareness. The protocol is named for the islet transplantation group at the University of Alberta in the Canadian city of Edmonton, where the protocol was first devised in the late 1990s.
Contents |
[edit] The Protocol
The Edmonton Protocol involves isolating islets from a cadaveric donor pancreas using a mixture of enzymes called Liberase™ (Roche). Each recipient receives islets from one to as many as three donors. The islets are infused into the patient's portal vein, and are then kept from being destroyed by the recipient's immune system through the use of two immunosuppressants, sirolimus and tacrolimus as well as a monoclonal antibody drug used in transplant patients called daclizumab.
[edit] History
Islet isolation and transplantation was pioneered by Paul Lacy throughout the 1960s. He and Walter Ballinger together were able to restore normoglycaemia in diabetic rats following the transplantation of isolated islets into the rodent's livers. Scientists have had a horrible time trying to translate Dr. Lacy's success in rodents to humans.
The Edmonton Protocol was primarily developed by Dr James Shapiro (transplant surgeon), Dr Jonathan Lakey (director of the Clinical Islet Isolation Laboratory), and Dr Edmond Ryan (Endocrinologist) at the University of Alberta Hospital. The first patient was treated using the Edmonton Protocol in March 1999. The protocol was first published in the New England Journal of Medicine in July 2000 (1).
The NEJM report was exciting for the diabetes field because 7 out of 7 patients undergoing the Edmonton Protocol remained insulin-independent after an average of 12 months.
[edit] A Current Review
It has recently been reported of 36 patients transplanted only 16 (44%) were insulin independent after 1 year, 10 (28%) had partial graft function after 1 year, and 10 (28%) had complete graft loss after 1 year. Insulin independence is not usually sustainable in the long term, but the transplanted islets still function enough to provide protection from severe hypoglycemic episodes and unawareness.
The major problem limiting islet transplantation therapy for type 1 diabetic individuals is the lack of organ donors.
[edit] References
- [1] Shapiro AMJ, Lakey JRT, Ryan EA. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-238.
- [2] Saffitz JE, Schmidt RE, McDaniel ML. Dr. Paul Eston Lacy, 1924–2005. American Journal of Pathology. 2005;167:299-300.
- [3] Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes. 2005 Jul;54(7):2060-9.
- [4] Sutherland DE, Gruessner RW, Gruessner AC. Pancreas transplantation for treatment of diabetes mellitus. World J Surg. 2001 Apr;25(4):487-96.
- [5] Shapiro AMJ, Ricordi C, Hering BJ et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318-1330.
- [6] O'Gorman D, Kin T, Murdoch T, Richer B, McGhee-Wilson D, Ryan EA, Shapiro AMJ, Lakey JRT. The standardization of pancreatic donors for islet isolations. Transplantation. 2005 Sep;80(6):801-806.
